NEW YORK (GenomeWeb) – Biodesix announced today that it has chosen Progenetics to market and distribute its liquid biopsy tests in Israel.
Under the terms of the agreement, Tel Aviv-based Progenetics will market and distribute Biodesix's GeneStrat and VeriStrat tests, which are available for clinical use in patients with non-small cell lung cancer (NSCLS).
GeneStrat measures circulating tumor DNA and RNA in blood to find KRAS and BRAF mutations; EGFR sensitization and resistance; and EML4-ALK, ROS1, and RET fusion variants. VeriStrat is a blood-based, proteomic test offering prediction and prognosis for patients with NSCLC.
Boulder, Colorado-based Biodesix said that the deal makes its Lung Reflex testing strategy available in the Middle East for the first time. Financial and other details of the agreement were not disclosed.
"With the incidence of lung cancer rising worldwide, and rising most dramatically outside the US, we are seeing great potential to expand the use of our tests into new global markets," Biodesix CEO David Brunel said in a statement.
In January, Biodesix signed a $38 million deal with Bioyong Industries for commercialization of VeriStrat in China.